Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel
NASDAQ:VOGX

Vogenx Q2 2026 Earnings Results & Report

Vogenx logo
$16.76 -0.38 (-2.22%)
As of 10/13/2026 04:00 PM Eastern

Vogenx reported Q2 2026 earnings on September 17, 2026. The company reported EPS of -$0.07.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
8:00 AM ET

Vogenx EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vogenx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Vogenx's Q2 2026 Quarterly reportQuarterly report
(10-Q)

Vogenx Q2 2026 Earnings FAQ

Vogenx (NASDAQ:VOGX) reported earnings of -$0.07 per share for Q2 2026. The report was announced on Thursday, September 17, 2026.

Vogenx Earnings Headlines

Vogenx Appoints Richard Gorman Chief Commercial Officer
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vogenx-appoints-richard-gorman-chief-130246010.html
VOGX Share News Today
October 8, 2026  |  uk.investing.comhttps://uk.investing.com/equities/vogenx-inc-news
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright.tc pixel
 |  True Market Insiders (Ad)
Vogenx (VOGX) Stock Forecast & Price Target
September 6, 2026  |  investing.comhttps://www.investing.com/equities/vogenx-inc-consensus-estimates
WBB Securities initiates coverage of Vogenx (VOGX) with speculative buy rating
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wbb-securities-initiates-coverage-of-vogenx-vogx-with-speculative-buy-rating/ar-AA2bzlqt
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
August 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/jones-served-as-sole-book-running-manager-for-vogenxs-81-3-million-initial-public-offering-302853039.html
See More Vogenx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vogenx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vogenx and other key companies, straight to your email.

About Vogenx

Vogenx (NASDAQ:VOGX), Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and autoimmune diseases. The company’s research centered on novel small-molecule therapies intended to modulate immune-system activity and reduce inflammation.

Vogenx’s lead investigational compound was VGX-1027, an orally administered anti-inflammatory agent studied for potential use in conditions including type 1 diabetes and other immune-mediated diseases. The company’s programs were primarily in the research and clinical-development stages, and its products were not broadly commercialized.

Vogenx was a U.S.-based biotechnology company. Publicly available information about its later operations, leadership, commercial activities and current corporate status is limited.

View Vogenx Profile
Earnings Tools